Respira Therapeuticsincis A Biopharmaceutical Company Based In California That Focuses On Developing Inhaled Therapeutics For Cardiopulmonary Diseasesthe Company Aims To Meet Unmet Patient Needs Through Advanced Drug Delivery Technologiesparticularly Using Proprietary Dry Powder Inhaler Devices And Particle Engineering To Enhance Drug Targeting To The Lung Periphery Respira S Product Pipeline Includes Rt234 Paha First In Class Inhaled Therapy For Pulmonary Arterial Hypertensionpah This Therapy Is Designed For As Needed Use To Alleviate Symptoms Like Breathlessness And Fatiguethe Aosa C Inhalercombined With Vardenafilallows For Consistent Dosing And Deep Lung Penetrationtargeting Small Airwaysthe Company Emphasizes Improving Exercise Tolerance And Quality Of Life For Pah Patientsparticularly Those Seeking Acute Symptom Reliefrt234 Pah Has Received Fda Orphan Drug Designationhighlighting Its Commitment To Addressing Rare Diseases
